Starling Oncology, Inc. (STLN), one of the largest value-based community oncology groups in the United States, trades far below the price levels Wall Street assigns it. After a steep post-earnings sell-off, investors are asking whether the shares can climb back to the $9 area. Here is a balanced look at what that target represents and what would need to go right.
The $9 central target reflects a small, uniformly bullish analyst base. Four firms with current, attributable targets were reviewed: B. Riley Securities lowered its target to $10 from $11 (Buy) on November 6, 2026; Lake Street cut its target to $8 from $10 (Buy) the same day; Needham reiterated a $9 target (Buy) on October 14, 2026; and BTIG held a $9 target (Buy). The arithmetic mean of $10, $8, $9 and $9 is $9.00, with an approximate low-to-high range of $8 to $10.
These figures are notably above pre-earnings consensus estimates from some aggregators, which had shown a higher average before the post-Q3 target cuts. The revisions followed a disappointing third-quarter report, in which EPS (earnings per share) missed expectations even as revenue beat. Analysts remain constructive, but the downward drift in targets signals reduced confidence in the near-term trajectory.
Shares closed at $3.62 on November 6, 2026, down about 46% in a single session after the November 5 earnings release, before a partial pre-market rebound. Reaching $9 from $3.62 requires a gain of roughly 149%, a very large move by any standard. The target also sits above the stock's 52-week high of $7.13, meaning the path would require the shares to recover their losses and then break into record territory.
Such a move would likely depend on a sustained re-rating of the company's value-based oncology and specialty pharmacy business. With trailing-twelve-month revenue near $620 million and a market capitalization around $369 million, the stock trades at a modest price-to-sales multiple, yet the company is still unprofitable on a net basis.
The core bull case is the company's shift toward capitated, delegated-risk contracts, in which it receives fixed per-member payments for managing cancer care. Management has guided for capitated revenue to reach about $300 million in 2027, a trajectory analysts have called "thesis-changing." The Starling Nexus portal, which centralizes utilization management and prior authorization across the affiliated network, is seen as a growth and margin lever.
Third-quarter revenue grew 24% year over year and came in above consensus, and the company generated positive adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). Continued execution on out-of-Florida expansion and specialty-pharmacy margins could support a re-rating toward the analyst range.
The immediate obstacle is earnings quality. Third-quarter EPS of ($0.13) missed the ($0.05) consensus by eight cents, and management narrowed full-year 2026 revenue guidance to $650–$660 million from $650–$670 million, below the roughly $665 million consensus. Lake Street noted investors "disliked the company's updated capitated revenue" commentary.
Structurally, the company remains unprofitable, carries a negative book value, and holds about $103 million in total debt against roughly $37 million in cash. Dilution is a live concern, with shares outstanding up nearly 20% year over year. Any further guidance cuts, capitation delays, or margin pressure could keep the stock anchored well below $9.
The stock's 52-week range spans roughly $2.32 to $7.13. The recent collapse took shares below both the 50-day moving average near $6.43 and the 200-day moving average near $4.76, leaving the price in deeply oversold territory with an RSI (relative strength index) near 25. Short interest is about 6.4% of the float, which could fuel sharp rallies on positive news but also adds to downside volatility. The $7.13 prior high stands as a major psychological and technical resistance zone that any move toward $9 would have to clear decisively.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms do not always disclose a uniform timeframe. For STLN, the most important items to watch are the next quarterly earnings report, updated capitated-revenue and 2027 guidance, progress on the Nexus platform and e-prescribing rollout, new delegated-risk contract announcements, and any analyst target revisions. Healthcare-policy developments affecting Medicare Advantage and Medicaid (including Medi-Cal) reimbursement are also directly relevant to the company's value-based model.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. For a volatile, news-sensitive name like STLN, these signals can help traders discover opportunities, monitor positions, and spot changing trends more efficiently than manual scanning. Traders interested in a systematic view of evolving setups can explore the AI Daily Buy/Sell Signals to see how the system reads current conditions.
The $9 target is the arithmetic mean of four Buy-rated analyst targets ranging from $8 to $10, and it implies roughly 149% upside from the latest close — a very large move that would require a full recovery from the post-earnings collapse plus new record highs. Support rests on capitated-revenue growth, the 2027 outlook, and a low revenue multiple. The principal obstacles are the Q3 EPS miss, narrowed guidance, persistent losses, dilution, and investor skepticism over the capitation trajectory. The analyst range itself signals uncertainty, with targets cut across the board after earnings. Investors should watch the next earnings report and capitation guidance rather than treat $9 as a forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, STLN has been loosely correlated with ASTH. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if STLN jumps, then ASTH could also see price increases.
| Ticker / NAME | Correlation To STLN | 1D Price Change % | ||
|---|---|---|---|---|
| STLN | 100% | -5.66% | ||
| ASTH - STLN | 33% Loosely correlated | +0.77% | ||
| AIRS - STLN | 33% Poorly correlated | -9.72% | ||
| WW - STLN | 29% Poorly correlated | -12.55% | ||
| SRTA - STLN | 26% Poorly correlated | -5.59% | ||
| NUTX - STLN | 26% Poorly correlated | +0.33% | ||
More | ||||